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Available online 10 August 2016AbstractPurpose: Perioperative chemotherapy confers a 3-year progression free survival advantage following resection of colorectal liver metastases
(CRLM), but is associated with significant toxicity. Chemoembolisation using drug eluting PVA microspheres loaded with irinotecan (DE-
BIRI) allows sustained delivery of drug directly to tumour, maximising response whilst minimising systemic exposure. This phase II single
arm study examined the safety and feasibility of DEBIRI before resection of CRLM.
Methods: Patients with resectable CRLM received lobar DEBIRI 1 month prior to surgery, with a radiological endpoint of near stasis. The
trial had a primary end-point of tumour resectability (R0 resection). Secondary end-points included safety, pathologic tumour response and
overall survival.
Results: 40 patients received DEBIRI, with a median dose of 103 mg irinotecan (range 64e175 mg). Morbidity was low (2.5%, CTCAE
grade 2) with no evidence of systemic chemotoxicity. All patients proceeded to surgery, with 38 undergoing resection (95%, R0 resection
rate 74%). 30-day post-operative mortality was 5% (n ¼ 2), with neither death TACE related. 66 lesions were resected, with histologic
major or complete pathologic response seen in 77.3% of targeted lesions. At median follow up of 40.6 months, 12 patients (34.3%) had
died of recurrent disease with a median overall survival of 50.9 months. Nominal 1, 3 and 5-year OS was 93, 78 & 49% respectively.
Conclusions: Resection after neoadjuvant DEBIRI for CRLM is feasible and safe. Single treatment with DEBIRI resulted in tumour path-
ologic response and median overall survival comparable to that seen after systemic neoadjuvant chemotherapy.
Registered at clinicaltrials.gov (NCT00844233).
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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).Introduction
For patients with irresectable colorectal liver metastases
(CRLM), standard of care remains first line systemic chemo-
therapy with the aim of shrinking tumour and bringing pa-
tients to resection. Response to chemotherapy is known
to correlate with resection rate1 and so it is vital that
patients are treated with the most effective chemotherapeuticess article under the CC BY-NC-ND license (http://creativecommons.org/
1867R.P. Jones et al. / EJSO 42 (2016) 1866e1872regimen possible. Patients who exhibit good pathological
response to chemotherapy on post-operative assessment
also have better overall survival2 with tumour replacement
by fibrosis associated with good long term outcome.3
The benefit of perioperative therapy for initially resect-
able disease is less clear. A large multicentre study
compared long term outcomes following 12 cycles of peri-
operative FOLFOX (6 before surgery, 6 after) against sur-
gery alone for initially resectable disease.4 Three year
progression free survival (PFS) was 36.2% in the perioper-
ative chemotherapy arm compared with 28.1% in the sur-
gery alone group but this did not translate into an
improvement in overall survival.5 The follow-on New
EPOC study aimed to evaluate the possible benefit of the
addition of monoclonal antibody therapy to epidermal
growth factor receptor (EGFR) in KRAS wild-type disease
by adding Cetuximab to FOLFOX in the neoadjuvant
setting. However, the authors reported a significantly shorter
PFS for combination therapy (14.1 vs. 20.5 months).6 The
reasons behind this different result to some palliative studies
remain unclear.7 Both studies demonstrated an increase in
surgical morbidity associated with neoadjuvant chemo-
therapy, suggesting that perioperative chemotherapy is not
without risk. Growing evidence also suggests that preopera-
tive therapy is associated with agent-specific patterns of
chemotherapy-associated liver injury (CALI),8e10 with a
clear association between CALI and 90-day post-operative
mortality.11 The decision to treat resectable disease with
neoadjuvant therapy is therefore a delicate balance between
risk and benefit, with little way of predicting which patients
are likely to gain a survival advantage.
The liver dominant pattern of metastatic colorectal can-
cer has led to the development of liver-directed therapy in
an effort to increase tumour exposure whilst reducing off-
target side effects. Drug eluting beads (DEBs) composed
of polyvinyl alcohol (PVA) microspheres loaded with irino-
tecan (DEBIRI, BTG, Farnham, United Kingdom) have
been used in heavily pre-treated irresectable patients. These
patients had received multiple lines of systemic therapy
prior to DEBIRI, with 2/3rds having radiological disease
control 6 months after treatment.12
There is no prospective evidence that it is safe to
perform hepatic surgery on patients who have been treated
with DEBIRI. The demonstration of safety in this setting is
vital before further trials assess the use of DEBIRI in a neo-
adjuvant or downsizing/induction protocol. The objective
of this study was therefore to assess the safety and efficacy
of neoadjuvant DEBIRI prior to resection of colorectal liver
metastases.
MethodsPatientsFigure 1. Trial schema for PARAGON study.
This was a pan-European multicentre single arm phase
II study. The trial had full ethical approval (South WestRegional Ethics Committee reference 08/H0206/51) and
was registered at clinicaltrials.gov (NCT00844233). Pa-
tients were identified as eligible for recruitment by a
specialist hepatobiliary multidisciplinary team meeting
(MDT). The trial had a recruitment target of 40 patients
successfully treated with DEBIRI. To be eligible for
recruitment, patients had to be aged between 18 and 80
years with an ECOG status 2. All had undergone an R0
primary colorectal resection and had liver-only metastatic
disease with a maximum of 4 potentially resectable colo-
rectal liver metastases. Patients were not allowed any previ-
ous exposure to irinotecan-based chemotherapy and did not
receive any other neoadjuvant chemotherapy. Resectability
was defined by the local hepatobiliary MDT after full stag-
ing with triple-phase CT chest/abdomen/pelvis, MRI with
liver-specific contrast and PET-CT.ProceduresAfter obtaining written informed consent to trial partic-
ipation, patients underwent baseline assessment. Transarte-
rial chemoembolization with DEBIRI (DEBIRI-TACE) was
performed within 4 weeks of baseline screening visit and 4
weeks prior to the planned resection (see Fig. 1). Treatment
consisted of a nominal dose of 2 ml of 100e300 mM diam-
eter beads preloaded with 200 mg of irinotecan supplied in
sterile lyophilized vials. The beads were hydrated with wa-
ter for injection, and mixed with a non-ionic contrast media
in the vial immediately prior to use according to the man-
ufacturers instructions.
Using a unilateral femoral approach, selective catheter-
isation of the hepatic artery was performed and an angio-
gram performed to identify any aberrant arterial anatomy
and verify portal patency. Initially, very selective
40 paƟents treated 
with DEBIRI
38 liver 
resecƟons 
2 unresectable
at surgery
1 HCC
2 periop deaths
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directly to the subsegment containing the tumour. As expe-
rience accumulated, a more proximal catheter placement
into the right or left hepatic artery was used. Once catheter
placement was confirmed, the embolic mixture was injected
slowly into the artery supplying the lobe where the lesion
was located until the blood flow became sluggish i.e. embo-
lization did not proceed to full stasis. If the embolization
endpoint was achieved before the delivery of 2 ml irinote-
can bead, the injection was stopped and the volume of
beads (and therefore drug) administered was recorded. No
patients received systemic neoadjuvant chemotherapy.
Four weeks after embolization patients underwent repeat
CT chest/abdomen/pelvis to assess radiological response,
followed by surgical resection. All patients underwent
resection during open surgery by an experienced hepato-
biliary surgeon.
Follow-up visits took place at 3, 6, 9 and 12 months
post-resection, followed by routine 6-monthly review.
These follow-up visits included clinical examination, mea-
surement of tumour markers (CEA) and triple-phase CT
chest/abdomen/pelvis. Irresectable recurrence was treated
with 5-FU based systemic chemotherapy according to local
protocol.
The trial had a primary endpoint of R0 tumour resect-
ability (defined as a negative margin of 1 mm on histo-
pathological assessment). Safety and toxicity after
DEBIRI was assessed according to NCI CTCAE v 3.0.13
Post-operative morbidity was measured using the
Clavien-Dindo classification.14 Radiological response was
assessed by triple-phase contrast enhanced CT performed
4 weeks after DEBIRI. Two independent reviewers per-
formed assessment of radiological response, and response
was agreed by consensus using RECIST criteria v 1.1.15
Pathological tumour response was assessed using a mini-
mum of 4 blocks stained with haematoxylin-eosin and re-
viewed by a specialised gastrointestinal pathologist. This
was performed using a validated method described by
Blazer et al.,16 whereby a estimation of the proportion of
lesion consisting of viable tumour cells, proportion consist-
ing of fibrotic tissue and proportion consisting of necrosis
within the whole tumour assessed across all 4 blocks was
made. Complete pathological response was defined as no
viable tumour cells, major response as 1%e49% of viable
tumour cells and minor response as >50% viable tumour
cells. Patients with no response (100% viable tumour)
were included in the minor response group. Where more
than one lesion was present, a mean % response across
all targeted lesions was calculated.35 eligible for follow-upStatistical analysis21 recurrences
12 deaths
Figure 2. CONSORT diagram of PARAGON study.Quantitative and qualitative variables were expressed as
medians (with range) and frequencies. Comparisons be-
tween groups were analysed with the chi-square test or
Fisher exact test for proportions and the ManneWhitneyU test for continuous variables. Overall and disease free
survival (OS, DFS) were calculated using the KaplaneMe-
ier method. To identify factors associated with OS and DFS
in the entire cohort, univariate analysis was performed. Fac-
tors for analysis were selected based on previous evidence
of prognostic value.17 For comparison of pathological
response rates in patients with more than one lesion, the
mean response score for all targeted lesions was used for
stratification. This was calculated by the sum of % viable
tumour in all lesions, divided by the number of resected le-
sions. Comparisons were made using log-rank test. All vari-
ables associated with p < 0.05 in the univariate
proportional hazards model were entered into a Cox pro-
portional hazards multivariate model using a forward step
wise procedure. p < 0.05 was considered significant. All
statistical analyses were performed using IBM SPSS Statis-
tics (v.20).
Results
Forty-nine patients were screened for recruitment, of
which 9 were not treated with DEBIRI. Reasons for non-
treatment were withdrawal of consent (n ¼ 2), did not
meet inclusion criteria (n ¼ 5), physician decision to offer
alternative therapy (n ¼ 1) and failure to gain peripheral ac-
cess for treatment with DEBIRI (n ¼ 1). Forty patients
were successfully treated with DEBIRI-TACE (see Fig. 2)
and patient demographics are outlined in Table 1. Median
patient age was 63, with nearly half of patients having a pri-
mary tumour located in the rectum (18/40, 45%). Twenty-
six (65%) had node positive primary disease, with 22
(55%) receiving adjuvant 5-FU based chemotherapy after
primary resection. Median time from resection of primary
tumour to time of diagnosis of liver metastases was 26.2
months, with 11 patients (27.5%) developing liver
Table 1
Patient demographics.
n %
Age Median, years 63 e
Sex Male 31 77.5
Female 9 22.5
Site of primary tumour Colon 22 55
Rectum 18 45
Primary tumour nodal status Positive 26 65
Negative 14 35
Adjuvant therapy for primary tumour Yes 22 55
No 18 45
Time from resection of primary tumour Median, months 26.2 e
Number of colorectal liver metastases 1 28 70
2 9 22.5
3 3 7.5
Longest diameter of CRLM >30 mm 22 45
<30 mm 18 55
KRAS status Mutant 7 22.6
Wild type 24 77.4
1869R.P. Jones et al. / EJSO 42 (2016) 1866e1872metastases within 12 months of primary resection. 28 pa-
tients (70%) had only 1 liver metastasis. Primary tumour
tissue for KRAS status was evaluable in 31 patients.Chemoembolisation procedureAll 40 patients underwent treatment with DEBIRI. A
single consultant interventional radiologist at each centre,
each with >5 years experience, performed the procedure.
Sixty-six discrete lesions were targeted, and patients
received a median dose of 119 mg irinotecan (range
25e200 mg). IV paracetamol, IV lignocaine and fentanyl
was used for peri-procedural pain control. No patients
required sedation, and 39 patients were discharged home
within 24 h. One patient was discharged after 48 h for so-
cial reasons. One patient developed post-DEBIRI pancrea-
titis (CTCAE grade 2, treated with supportive care) and was
readmitted after 48 h (2.5% morbidity). After an uneventful
3-day inpatient stay they were discharged home, and under-
went liver resection 95 days after TACE. No patients devel-
oped any systemic toxicity to irinotecan, or required any
post-discharge pain medication.SurgeryAll forty patients proceeded to surgery. Median interval
from DEBIRI-TACE to surgery was 30 days (IQR 27-35).
At laparotomy, 2 patients were found to have unresectable
disseminated peritoneal disease neither of which was iden-
tified on preoperative imaging. Thirty-eight patients there-
fore underwent liver resection (95% resection rate).
Twelve patients (32%) underwent anatomical resection (7
left hemihepatectomy, 4 left lateral sectionectomy, 1 right
hemihepatectomy), with the remainder undergoing non-
anatomical metastectomies. Four previously undetected in-
trahepatic lesions were found in three patients. A total of
sixty-eight lesions were therefore resected.Two patients died within 30 days of surgery (30-day
mortality 5%), neither of which was TACE related. One pa-
tient died from haemo-pneumo-mediastinum following
false route insertion of a central line on the critical care
unit on the day of surgery. The second patient died 8
days after surgery, having developed aspiration pneumonia
followed by multi-organ dysfunction syndrome (MODS).
Eleven patients (27.5%) developed complications (Dindo-
Clavien grade 1e3), with 1 (2.5%) developing grade 3
complication (bile leak requiring percutaneous drainage).Tumour responseOne patient was found to have hepatocellular carci-
noma on histopathology and so was excluded from further
pathological and long-term analysis. Four intraoperatively
detected untreated lesions were also excluded from anal-
ysis. The remaining 63 treated lesions from 37 resected
patients were assessed for pathological response. 74% of
lesions were resected with an R0 margin, with 26% under-
going an R1 resection. Median tumour diameter was
21 mm (range 4e150 mm). Median viable tumour was
20% (range 0e100), necrosis 50% (range 0e100) and
fibrosis 17% (range 0e70). Tumour response was defined
as complete in 11 lesions (17%), major in 37 lesions
(59%), minor in 14 lesions (22%) and no response in 1
lesion (2%) (See Fig. 3). Tumour response assessed by
RECIST criteria demonstrated stable disease (22 patients,
55%), partial response (1 patient, 2.5%) or progressive
disease (11 patients, 27.5%). There was no correlation be-
tween radiological response rates and pathological tumour
response. As previously reported, there was no difference
in pathological response between subsegmental and lobar
embolisation.18Long-term outcomeSurvival analysis was performed on 35 of 38 patients
who underwent hepatectomy for CRLM (2 early post-
operative deaths were excluded from analysis, as was
one patient found to have hepatocellular carcinoma on his-
topathology). No patients received systemic adjuvant ther-
apy after liver resection. At a median follow up of 40.6
months, 12 patients (34.3%) had died of recurrent disease
giving a median overall survival of 50.9 months. Nominal
1, 3 and 5-year OS was 93, 78 & 49% respectively (see
Fig. 4). There were 21 recurrences at median follow-up,
of whom 11 (52.3%) had liver-only recurrence. Median
disease free survival was 19.7 months, with a 1, 3 and
5-year actuarial disease free survival of 68, 44 and 38%
respectively. Results of univariate and multivariate predic-
tors of overall survival are detailed in Table 2. Gender was
the only factor associated with OS on univariate analysis,
but was not significant on multivariate analysis. No statis-
tically significant predictors of disease free survival were
identified.
Figure 3. Representative photomicrographs of pathological tumour response after treatment with DEBIRI. (A) Major response e between 1 and 49% viable
tumour. Magnification  10 (B) Complete response e no viable tumour within lesion. Magnification  20. > ¼ DEBIRI microsphere in tissue vasculature,
* ¼ tissue fibrosis, Y ¼ tumour necrosis, N ¼ tumour.
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The decision to treat resectable CRLM with neoadjuvant
therapy is complex, with clinicians required to balance the
potential long-term benefits with the risk of toxic side ef-
fects. The global model of cancer-drug development aims
to shift this balance through novel agents targeting a narrow
selection of molecular changes that occur in only a minor-
ity of tumours. This approach leads to rising cancer care
costs, often without proportional gains in outcome.19 By
contrast, DEBIRI offers the potential to maximize tumour
targeting whilst minimizing off-target side effects by phys-
ically localizing a commonly used cytotoxic agent directly
to the tumour. The overall cost per treatment therefore re-
mains an order of magnitude lower than for existing first-
line biologic based systemic therapy.
This trial clearly demonstrated that administration of
DEBIRI was safe, with no technical complications associ-
ated with the embolization procedure. These results0  1  2  3  4  5  6
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Figure 4. Kaplan Meier curve demonstrating overall and disease free sur-
vival following liver resection after neoadjuvant DEBIRI. Table shows
number at risk.compare favourably with reports describing alternative
methods of liver directed therapy, such as hepatic arterial
infusion pumps.20,21 Contemporary trials assessing irinote-
can based therapies for systemic disease report dose-
limiting side effects (diarrhea and neutropenia) in
10e15% of cases22 and the use of neoadjuvant systemic
therapy for initially resectable disease remains controver-
sial.5,6,24 Preliminary pharmacokinetic modelling from
this study suggests that systemic exposure to irinotecan af-
ter DEBIRI is low25 and the absence of systemic toxicity
reported in this trial suggest that DEBIRI would be a
rational approach in such cases where the risk: benefit bal-
ance in favour of treatment may be marginal. These results
also imply that DEBIRI may be used in combination with
existing systemic therapies without a significant increase
in treatment-related toxicity, although this would need
confirmation in a prospective setting.
Surgical safety was not compromised by neoadjuvant
treatment with DEBIRI. Hepatic resection was performed
in thirty-eight of forty cases (resectability rate 95%), with
two patients having widespread intraperitoneal carcinoma-
tosis discovered at laparotomy. This pattern of disease is
difficult to detect on preoperative imaging, and the delay
of 4 weeks between DEBIRI-TACE and surgery would
seem unlikely to be sufficient interval for the development
of micrometastases. 74% of lesions treated with DEBIRI
were resected with an R0 margin, with 26% R1 resection.
This resection rate is comparable with other series reporting
resection of CRLM without neoadjuvant therapy,26 and
likely reflects the easily resectable nature of patients re-
cruited to this trial. Post-operative surgical mortality (5%)
was higher than other reports which commonly cite 30-
day mortality for hepatectomy after neoadjuvant chemo-
therapy consistently lower than 2%.4,11,27 However, it
seems unlikely that either of the deaths seen in this study
were directly related to the neoadjuvant administration of
DEBIRI. One patient died from anesthetic misadventure,
whilst a second died from a recognized postoperative
complication. Post-operative morbidity was in keeping
with other published series.28
Table 2
Univariate analysis of clinicopathological variables associated with overall
survival after liver resection following neoadjuvant DEBIRI.
n ¼ 35
(%)
Median
OS (months)
Number
of deaths
P
Sex Male 26 (74%) 55.1 6 0.04
Female 9 (26%) 41.0 6
Age <65 18 (51%) 51.7 5 0.88
>65 17 (49%) 49.5 7
Interval from
primary to
secondary
<12 months 11 (31%) 58.1 2 0.11
>12 months 24 (69%) 46.7 10
Nodal status
of primary
Positive 17 (49%) 48.3 6 0.60
Negative 18 (51%) 52.8 6
Size of largest
lesion, mm
<30 18 (51%) 54.5 5 0.34
>30 17 (49%) 45.7 7
Margin R0 19 (54%) 53.9 4 0.40
R1 16 (46%) 49.5 8
Pathological
response
Minor 5 (14%) 52.0 2 0.23
Major 22 (86%) 42.5 9
Complete 8 (23%) 60.0 1
Ras status Mutant 7 (77%) 45.8 2 0.58
Wild-type 24 (69%) 53.0 7
Number
of lesions
1 18 (51%) 45.9 8 0.24
>1 17 (49%) 55.9 4
RECIST
response
Partial
response
1 (3%) 55.0 0 0.34
Stable
disease
22 (63%) 48.7 8
Progressive
disease
11 (31%) 53.7 6
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of lesions showing a major or complete pathological
response - comparable to that seen after six cycles of sys-
temic FOLFOX/FOLFIRI.16 By contrast, radiological
response rates were very low with only 2.5% of
patients demonstrating response by RECIST criteria. RE-
CIST remains the gold standard for assessing response of
solid tumours but there is growing evidence that traditional
size-based criteria (such as RECIST and mRECIST) do not
optimally reflect tumour response to novel therapies such
as DEBIRI.29e31 The trial protocol allowed only 4 weeks
between treatment and resection, and it may also be that
inadequate time had passed to allow maximal tumour
response (as measured by reduction in tumour size).
It has also been suggested that peritumoral edema in the
immediate post-DEBIRI phase may lead to a transient in-
crease in tumour size on scanning.31 This may have an
impact on potential future roles for DEBIRI in the down-
staging or initially irresectable disease.
The mechanism of action of DEBIRI has not yet been
fully elucidated. Although pathological response rates are
impressive, it is unclear whether this is predominantly
due to the embolisation effect, local cytotoxic drug effect
or a combination of the two. Preliminary animal modelling
suggests that bland bead embolisation is ineffectivecompared to treatment with drug-loaded bead,32 whilst
early clinical studies have suggested that drug activation
in normal liver surrounding tumour (i.e. off-target delivery)
is a predictor of treatment response.25 It therefore seems
likely that targeted drug delivery is a significant contributor
to the efficacy of DEBIRI. Stage IV colorectal cancer is a
systemic disease, and it would appear logical that the even-
tual role for DEBIRI will be alongside a systemic therapy
in an effort to maximize treatment of liver dominant dis-
ease. In this setting, addition of DEBIRI to FOLFOX
may increase response and therefore resection rates without
a significant increase in toxicity.33 However, the optimal
systemic therapy backbone requires clarification. If emboli-
sation is an important factor in the mechanism of action,
systemic anti-angiogenic agents (such as Bevacizumab
and Aflibercept) are likely to have a synergistic effect by
preventing revascularization of tumour after treatment.
Although we have not directly addressed the subsequent
multi-modal therapies offered to these patients following dis-
ease recurrence, the 5-year survival of 49% reported in this
trial reinforces the excellent long-term outcomes associated
with liver resection for CRLM in this group of patients. At
median follow-up of 40 months, 53% patients had developed
recurrent disease, of which approximately half had liver-only
recurrence. Given that the aim of the study was to assess the
feasibility of resecting treated liver, rather than reducing
occult disease burden, these figures are unsurprising and in
keeping with other contemporary series.
In conclusion, this trial clearly demonstrates the safety
and efficacy of neoadjuvant DEBIRI in patients with easily
resectable colorectal liver metastases. This treatment can be
delivered prior to surgery, with minimal morbidity and
without any delay in primary treatment. DEBIRI has no
impact on resectability of tumour or on surgical outcomes
and the impressive pathological response rates after a single
treatment with DEBIRI are comparable with that seen after
multiple cycles of systemic chemotherapy, with no evi-
dence of systemic toxicity. The results of this preliminary
study will be used to guide further prospective studies on
the precise role of DEBIRI in the management of CRLM.
This seems likely to be alongside systemic therapies, either
in a true neoadjuvant model or as an adjunct to induction
chemotherapy for initially irresectable disease, where con-
version to resectability is the primary aim of therapy. A bet-
ter understanding of the interactions between DEBIRI and
other agents is therefore crucial. With treatment value
becoming an increasingly important cancer metric, formal
health economic assessment of the efficacy of treatments
like DEBIRI is also likely to be critical in defining its
role in the multi-modality management of colorectal
cancer.
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